| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000029849 |
| Receipt No. | R000034018 |
| Official scientific title of the study | The effect of a combination of dietary intervention and functional therapy using ingredient analytical instrument in fatty liver patients: a randomized controlled trial. |
| Date of disclosure of the study information | 2017/11/07 |
| Last modified on | 2018/11/07 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | The effect of a combination of dietary intervention and functional therapy using ingredient analytical instrument in fatty liver patients: a randomized controlled trial. | |
| Title of the study (Brief title) | Dietary and functional intervention study. | |
| Region |
|
|
| Condition | ||||
| Condition | fatty liver diseases
Non-alcoholic Fatty Liver Diseases Non-alcoholic steatohepatitis |
|||
| Classification by specialty |
|
|||
| Classification by malignancy | Others | |||
| Genomic information | NO | |||
| Objectives | |
| Narrative objectives1 | Non-alcoholic fatty liver disease (NAFLD) and a nonalcoholic steatohepatitis (NASH) is required management of diet, and recommended to do a continued exercise. Purpose of this study is to explore the efficacy of the multidisciplinary team approach to support diet therapy accompanying nutritional guidance and exercise instruction accompanying exercise instruction together. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Changes from baseline of skeletal muscle mass; body fat mass; basal metabolism rate; and visceral fat area, at one, two, three, six, nine, and 12 months after the start of the intervention. |
| Key secondary outcomes | Motor function test (6 minutes walking distance, grip strength,Knee extension muscle strength), blood biochemical test (AST,ALT, GTP, TG,HDL-cho LDL-cho, BS, insulin, iron, ferritin, FFA Hyaluronic acid, type IV collagen 7S, etc.), abdominal supersonic Wave test (liver hardness, rate of change of hepatic fat mass). |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -no one is blinded |
| Control | Active |
| Stratification | NO |
| Dynamic allocation | NO |
| Institution consideration | Institution is not considered as adjustment factor. |
| Blocking | NO |
| Concealment | No need to know |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Educational intervention | |
| Interventions/Control_2 | 12 months | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Patient diagnosed as fatty liver
2. Patient aged over 20 years old and under 75 3. PS 0 - 1 (ECOG) 4. Patient can intake orally 5. Informed Consent has been obtained in writing form.by himself / herself about examination participation |
|||
| Key exclusion criteria | 1. Patient who has been infected with hepatitis virus
2. Patient has a clear drinking history (Alcohol amount: over 20 g / day) 3. patient who has difficulties in doing exercise, such as any joint pain, kidney dysfunction or heart disease 4. Patient who has poorly controlled diabetes 5. Patient who was judged as inappropriate for this research by physichans. |
|||
| Target sample size | 26 | |||
| Research contact person | |
| Name of lead principal investigator | Masashi FURUTA |
| Organization | National Center for Global Health and Medicine |
| Division name | The Research Center for Hepatitis and Immunology |
| Address | 1-7-1 Kohnodai, Ichikawa-City, Chiba, Japan |
| TEL | 047-372-3501 |
| masashi.furuta@med.toho-u.ac.jp | |
| Public contact | |
| Name of contact person | Masashi FURUTA |
| Organization | National Center for Global Health and Medicine |
| Division name | The Research Center for Hepatitis and Immunology |
| Address | 1-7-1 Kohnodai, Ichikawa-City, Chiba, Japan |
| TEL | 047-372-3501 |
| Homepage URL | |
| masashi.furuta@med.toho-u.ac.jp | |
| Sponsor | |
| Institute | National Center for Global Health and Medicine
The Research Center for Hepatitis and Immunology Department of Liver Disease |
| Institute | |
| Department | |
| Funding Source | |
| Organization | None |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 国立国際医療研究センター国府台病院(千葉県)
National Center for Global Health and Medicine Konodai Hospital |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000034018 |